The therapeutic effect and onset of action of anagrelide for the treatment of primary thrombocythemia varies from person to person, and there is no exact point in time for the onset of action; some clinical trials have found that the median onset of action of anagrelide for the treatment of primary thrombocythemia is 7 days.
Anagrelide is an oral antiplatelet aggregation drug, which can be used to treat primary thrombocythemia, true erythrocytosis, primary myelofibrosis and other causes of thrombocytosis. It has a very important role in the treatment of primary thrombocythemia, with remarkable effects and positive relief of the condition.
Because of individual differences, the therapeutic effect and onset time of primary thrombocythemia patients after receiving anagrelide treatment are not the same, and its onset time is related to the stage of the disease, personal constitution, drug tolerance, etc. There is no exact time point, and according to clinical trials, its median onset time is 7 days.
Anagrelide needs to be used under the guidance of a doctor, and patients diagnosed with primary thrombocythemia are advised to consult a doctor in a timely manner and actively receive appropriate treatment.